Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
Identifieur interne : 001468 ( Istex/Corpus ); précédent : 001467; suivant : 001469Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
Auteurs : Bruno Dubois ; David Burn ; Christopher Goetz ; Dag Aarsland ; Richard G. Brown ; Gerald A. Broe ; Dennis Dickson ; Charles Duyckaerts ; Jefferey Cummings ; Serge Gauthier ; Amos Korczyn ; Andrew Lees ; Richard Levy ; Irene Litvan ; Yoshikuni Mizuno ; Ian G. Mckeith ; C. Warren Olanow ; Werner Poewe ; Cristina Sampaio ; Eduardo Tolosa ; Murat EmreSource :
- Movement Disorders [ 0885-3185 ] ; 2007-12-15.
English descriptors
- KwdEn :
- Aarsland, Abstract responses, Antidepressant treatment, Apathy, Arch neurol, Beck depression inventory, Behavioral changes, Behavioral symptoms, Caregiver, Caregiver interview, Clin, Clin neuropsychol, Clinical features, Clinical monitoring, Clinician, Cognitive, Cognitive changes, Cognitive impairment, Cognitive impairments, Correct responses, Cutoff, Daily life, Demented patients, Dementia, Diagnostic criteria, Diagnostic procedures, Digit, Digit span, Digit span test, Disease dementia, Disorder, Dopaminergic drugs, Dubois, Dysexecutive syndrome, Dysfunction, Executive dysfunction, Executive function, Executive functions, Explicit memory, Frontal assessment battery, Frontal lobes, Geriatr psychiatry, Geriatric depression scale, Hallucination, Hamilton depression rating scale, Impairment, Incorrect responses, Lewy bodies, Major depression, Mattis dementia rating scale, Memory impairment, Mental organization, Mmse, Motor component, Movement disorders, Movement disorders unit, Neurol, Neurol neurosurg psychiatry, Neurology, Neuropsychiatric, Neuropsychiatric disturbances, Neuropsychiatric features, Neuropsychiatric inventory, Neuropsychiatric symptoms, Neuropsychol, Neuropsychological, Neuropsychological methods, Newcastle university, Normative date, Parkinson disease, Parkinsonian patients, Particular expertise, Perseverative errors, Pharmacological trials, Pill questionnaire, Psychiatry, Psychosis, Research institute, Research studies, Retrieval, Salpetriere hospital, Several studies, Sinai school, Space perception battery, Spatial span, State examination, Task force, Visual hallucinations, Visual object, Wide range.
- Teeft :
- Aarsland, Abstract responses, Antidepressant treatment, Apathy, Arch neurol, Beck depression inventory, Behavioral changes, Behavioral symptoms, Caregiver, Caregiver interview, Clin, Clin neuropsychol, Clinical features, Clinical monitoring, Clinician, Cognitive, Cognitive changes, Cognitive impairment, Cognitive impairments, Correct responses, Cutoff, Daily life, Demented patients, Dementia, Diagnostic criteria, Diagnostic procedures, Digit, Digit span, Digit span test, Disease dementia, Disorder, Dopaminergic drugs, Dubois, Dysexecutive syndrome, Dysfunction, Executive dysfunction, Executive function, Executive functions, Explicit memory, Frontal assessment battery, Frontal lobes, Geriatr psychiatry, Geriatric depression scale, Hallucination, Hamilton depression rating scale, Impairment, Incorrect responses, Lewy bodies, Major depression, Mattis dementia rating scale, Memory impairment, Mental organization, Mmse, Motor component, Movement disorders, Movement disorders unit, Neurol, Neurol neurosurg psychiatry, Neurology, Neuropsychiatric, Neuropsychiatric disturbances, Neuropsychiatric features, Neuropsychiatric inventory, Neuropsychiatric symptoms, Neuropsychol, Neuropsychological, Neuropsychological methods, Newcastle university, Normative date, Parkinson disease, Parkinsonian patients, Particular expertise, Perseverative errors, Pharmacological trials, Pill questionnaire, Psychiatry, Psychosis, Research institute, Research studies, Retrieval, Salpetriere hospital, Several studies, Sinai school, Space perception battery, Spatial span, State examination, Task force, Visual hallucinations, Visual object, Wide range.
Abstract
A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21844
Links to Exploration step
ISTEX:6E57B2447643E9AF227ECAC3B1DF8B327F449F2DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: bruno.dubois@psl.aphp.fr</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Neurology Department and Inserm U610, Salpêtrière Hospital, 47 Bd de l'Hôpital, Paris 75013, France</mods:affiliation></affiliation></author><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher" sort="Goetz, Christopher" uniqKey="Goetz C" first="Christopher" last="Goetz">Christopher Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</mods:affiliation></affiliation><affiliation><mods:affiliation>School of Medicine, University of Bergen, Norway</mods:affiliation></affiliation></author><author><name sortKey="Brown, Richard G" sort="Brown, Richard G" uniqKey="Brown R" first="Richard G." last="Brown">Richard G. Brown</name><affiliation><mods:affiliation>Department of Psychology, King's College, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Broe, Gerald A" sort="Broe, Gerald A" uniqKey="Broe G" first="Gerald A." last="Broe">Gerald A. Broe</name><affiliation><mods:affiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</mods:affiliation></affiliation></author><author><name sortKey="Dickson, Dennis" sort="Dickson, Dennis" uniqKey="Dickson D" first="Dennis" last="Dickson">Dennis Dickson</name><affiliation><mods:affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Duyckaerts, Charles" sort="Duyckaerts, Charles" uniqKey="Duyckaerts C" first="Charles" last="Duyckaerts">Charles Duyckaerts</name><affiliation><mods:affiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Cummings, Jefferey" sort="Cummings, Jefferey" uniqKey="Cummings J" first="Jefferey" last="Cummings">Jefferey Cummings</name><affiliation><mods:affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name><affiliation><mods:affiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Korczyn, Amos" sort="Korczyn, Amos" uniqKey="Korczyn A" first="Amos" last="Korczyn">Amos Korczyn</name><affiliation><mods:affiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Levy, Richard" sort="Levy, Richard" uniqKey="Levy R" first="Richard" last="Levy">Richard Levy</name><affiliation><mods:affiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><mods:affiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Mckeith, Ian G" sort="Mckeith, Ian G" uniqKey="Mckeith I" first="Ian G." last="Mckeith">Ian G. Mckeith</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6E57B2447643E9AF227ECAC3B1DF8B327F449F2D</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21844</idno><idno type="url">https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001468</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001468</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: bruno.dubois@psl.aphp.fr</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Neurology Department and Inserm U610, Salpêtrière Hospital, 47 Bd de l'Hôpital, Paris 75013, France</mods:affiliation></affiliation></author><author><name sortKey="Burn, David" sort="Burn, David" uniqKey="Burn D" first="David" last="Burn">David Burn</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher" sort="Goetz, Christopher" uniqKey="Goetz C" first="Christopher" last="Goetz">Christopher Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</mods:affiliation></affiliation><affiliation><mods:affiliation>School of Medicine, University of Bergen, Norway</mods:affiliation></affiliation></author><author><name sortKey="Brown, Richard G" sort="Brown, Richard G" uniqKey="Brown R" first="Richard G." last="Brown">Richard G. Brown</name><affiliation><mods:affiliation>Department of Psychology, King's College, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Broe, Gerald A" sort="Broe, Gerald A" uniqKey="Broe G" first="Gerald A." last="Broe">Gerald A. Broe</name><affiliation><mods:affiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</mods:affiliation></affiliation></author><author><name sortKey="Dickson, Dennis" sort="Dickson, Dennis" uniqKey="Dickson D" first="Dennis" last="Dickson">Dennis Dickson</name><affiliation><mods:affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Duyckaerts, Charles" sort="Duyckaerts, Charles" uniqKey="Duyckaerts C" first="Charles" last="Duyckaerts">Charles Duyckaerts</name><affiliation><mods:affiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Cummings, Jefferey" sort="Cummings, Jefferey" uniqKey="Cummings J" first="Jefferey" last="Cummings">Jefferey Cummings</name><affiliation><mods:affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name><affiliation><mods:affiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</mods:affiliation></affiliation></author><author><name sortKey="Korczyn, Amos" sort="Korczyn, Amos" uniqKey="Korczyn A" first="Amos" last="Korczyn">Amos Korczyn</name><affiliation><mods:affiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Levy, Richard" sort="Levy, Richard" uniqKey="Levy R" first="Richard" last="Levy">Richard Levy</name><affiliation><mods:affiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><mods:affiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Mckeith, Ian G" sort="Mckeith, Ian G" uniqKey="Mckeith I" first="Ian G." last="Mckeith">Ian G. Mckeith</name><affiliation><mods:affiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</mods:affiliation></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation><mods:affiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Movement Disorders</title><title level="j" type="alt">MOVEMENT DISORDERS</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><biblScope unit="vol">22</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2314">2314</biblScope><biblScope unit="page" to="2324">2324</biblScope><biblScope unit="page-count">11</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-12-15">2007-12-15</date></imprint><idno type="ISSN">0885-3185</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aarsland</term><term>Abstract responses</term><term>Antidepressant treatment</term><term>Apathy</term><term>Arch neurol</term><term>Beck depression inventory</term><term>Behavioral changes</term><term>Behavioral symptoms</term><term>Caregiver</term><term>Caregiver interview</term><term>Clin</term><term>Clin neuropsychol</term><term>Clinical features</term><term>Clinical monitoring</term><term>Clinician</term><term>Cognitive</term><term>Cognitive changes</term><term>Cognitive impairment</term><term>Cognitive impairments</term><term>Correct responses</term><term>Cutoff</term><term>Daily life</term><term>Demented patients</term><term>Dementia</term><term>Diagnostic criteria</term><term>Diagnostic procedures</term><term>Digit</term><term>Digit span</term><term>Digit span test</term><term>Disease dementia</term><term>Disorder</term><term>Dopaminergic drugs</term><term>Dubois</term><term>Dysexecutive syndrome</term><term>Dysfunction</term><term>Executive dysfunction</term><term>Executive function</term><term>Executive functions</term><term>Explicit memory</term><term>Frontal assessment battery</term><term>Frontal lobes</term><term>Geriatr psychiatry</term><term>Geriatric depression scale</term><term>Hallucination</term><term>Hamilton depression rating scale</term><term>Impairment</term><term>Incorrect responses</term><term>Lewy bodies</term><term>Major depression</term><term>Mattis dementia rating scale</term><term>Memory impairment</term><term>Mental organization</term><term>Mmse</term><term>Motor component</term><term>Movement disorders</term><term>Movement disorders unit</term><term>Neurol</term><term>Neurol neurosurg psychiatry</term><term>Neurology</term><term>Neuropsychiatric</term><term>Neuropsychiatric disturbances</term><term>Neuropsychiatric features</term><term>Neuropsychiatric inventory</term><term>Neuropsychiatric symptoms</term><term>Neuropsychol</term><term>Neuropsychological</term><term>Neuropsychological methods</term><term>Newcastle university</term><term>Normative date</term><term>Parkinson disease</term><term>Parkinsonian patients</term><term>Particular expertise</term><term>Perseverative errors</term><term>Pharmacological trials</term><term>Pill questionnaire</term><term>Psychiatry</term><term>Psychosis</term><term>Research institute</term><term>Research studies</term><term>Retrieval</term><term>Salpetriere hospital</term><term>Several studies</term><term>Sinai school</term><term>Space perception battery</term><term>Spatial span</term><term>State examination</term><term>Task force</term><term>Visual hallucinations</term><term>Visual object</term><term>Wide range</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Aarsland</term><term>Abstract responses</term><term>Antidepressant treatment</term><term>Apathy</term><term>Arch neurol</term><term>Beck depression inventory</term><term>Behavioral changes</term><term>Behavioral symptoms</term><term>Caregiver</term><term>Caregiver interview</term><term>Clin</term><term>Clin neuropsychol</term><term>Clinical features</term><term>Clinical monitoring</term><term>Clinician</term><term>Cognitive</term><term>Cognitive changes</term><term>Cognitive impairment</term><term>Cognitive impairments</term><term>Correct responses</term><term>Cutoff</term><term>Daily life</term><term>Demented patients</term><term>Dementia</term><term>Diagnostic criteria</term><term>Diagnostic procedures</term><term>Digit</term><term>Digit span</term><term>Digit span test</term><term>Disease dementia</term><term>Disorder</term><term>Dopaminergic drugs</term><term>Dubois</term><term>Dysexecutive syndrome</term><term>Dysfunction</term><term>Executive dysfunction</term><term>Executive function</term><term>Executive functions</term><term>Explicit memory</term><term>Frontal assessment battery</term><term>Frontal lobes</term><term>Geriatr psychiatry</term><term>Geriatric depression scale</term><term>Hallucination</term><term>Hamilton depression rating scale</term><term>Impairment</term><term>Incorrect responses</term><term>Lewy bodies</term><term>Major depression</term><term>Mattis dementia rating scale</term><term>Memory impairment</term><term>Mental organization</term><term>Mmse</term><term>Motor component</term><term>Movement disorders</term><term>Movement disorders unit</term><term>Neurol</term><term>Neurol neurosurg psychiatry</term><term>Neurology</term><term>Neuropsychiatric</term><term>Neuropsychiatric disturbances</term><term>Neuropsychiatric features</term><term>Neuropsychiatric inventory</term><term>Neuropsychiatric symptoms</term><term>Neuropsychol</term><term>Neuropsychological</term><term>Neuropsychological methods</term><term>Newcastle university</term><term>Normative date</term><term>Parkinson disease</term><term>Parkinsonian patients</term><term>Particular expertise</term><term>Perseverative errors</term><term>Pharmacological trials</term><term>Pill questionnaire</term><term>Psychiatry</term><term>Psychosis</term><term>Research institute</term><term>Research studies</term><term>Retrieval</term><term>Salpetriere hospital</term><term>Several studies</term><term>Sinai school</term><term>Space perception battery</term><term>Spatial span</term><term>State examination</term><term>Task force</term><term>Visual hallucinations</term><term>Visual object</term><term>Wide range</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>dementia</json:string><json:string>neurology</json:string><json:string>neuropsychological</json:string><json:string>mmse</json:string><json:string>caregiver</json:string><json:string>neurol</json:string><json:string>clinician</json:string><json:string>psychosis</json:string><json:string>movement disorders</json:string><json:string>dysfunction</json:string><json:string>impairment</json:string><json:string>digit</json:string><json:string>clin</json:string><json:string>neuropsychol</json:string><json:string>aarsland</json:string><json:string>dubois</json:string><json:string>hallucination</json:string><json:string>cognitive</json:string><json:string>diagnostic criteria</json:string><json:string>diagnostic procedures</json:string><json:string>parkinsonian patients</json:string><json:string>cutoff</json:string><json:string>task force</json:string><json:string>neurol neurosurg psychiatry</json:string><json:string>retrieval</json:string><json:string>geriatric depression scale</json:string><json:string>geriatr psychiatry</json:string><json:string>behavioral symptoms</json:string><json:string>major depression</json:string><json:string>clin neuropsychol</json:string><json:string>executive functions</json:string><json:string>daily life</json:string><json:string>cognitive changes</json:string><json:string>neuropsychiatric</json:string><json:string>correct responses</json:string><json:string>lewy bodies</json:string><json:string>research studies</json:string><json:string>disease dementia</json:string><json:string>neuropsychological methods</json:string><json:string>particular expertise</json:string><json:string>clinical features</json:string><json:string>mattis dementia rating scale</json:string><json:string>digit span</json:string><json:string>memory impairment</json:string><json:string>executive dysfunction</json:string><json:string>frontal assessment battery</json:string><json:string>neuropsychiatric inventory</json:string><json:string>neuropsychiatric symptoms</json:string><json:string>cognitive impairment</json:string><json:string>frontal lobes</json:string><json:string>salpetriere hospital</json:string><json:string>apathy</json:string><json:string>perseverative errors</json:string><json:string>dysexecutive syndrome</json:string><json:string>behavioral changes</json:string><json:string>movement disorders unit</json:string><json:string>digit span test</json:string><json:string>clinical monitoring</json:string><json:string>spatial span</json:string><json:string>abstract responses</json:string><json:string>caregiver interview</json:string><json:string>pill questionnaire</json:string><json:string>motor component</json:string><json:string>pharmacological trials</json:string><json:string>dopaminergic drugs</json:string><json:string>wide range</json:string><json:string>demented patients</json:string><json:string>explicit memory</json:string><json:string>several studies</json:string><json:string>visual object</json:string><json:string>space perception battery</json:string><json:string>visual hallucinations</json:string><json:string>antidepressant treatment</json:string><json:string>hamilton depression rating scale</json:string><json:string>beck depression inventory</json:string><json:string>sinai school</json:string><json:string>neuropsychiatric disturbances</json:string><json:string>incorrect responses</json:string><json:string>parkinson disease</json:string><json:string>research institute</json:string><json:string>arch neurol</json:string><json:string>state examination</json:string><json:string>executive function</json:string><json:string>newcastle university</json:string><json:string>neuropsychiatric features</json:string><json:string>cognitive impairments</json:string><json:string>mental organization</json:string><json:string>normative date</json:string><json:string>psychiatry</json:string><json:string>disorder</json:string></teeft></keywords><author><json:item><name>Bruno Dubois MD</name><affiliations><json:string>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</json:string><json:string>E-mail: bruno.dubois@psl.aphp.fr</json:string><json:string>Correspondence address: Neurology Department and Inserm U610, Salpêtrière Hospital, 47 Bd de l'Hôpital, Paris 75013, France</json:string></affiliations></json:item><json:item><name>David Burn MD</name><affiliations><json:string>Institute for Ageing and Health, Newcastle University, United Kingdom</json:string></affiliations></json:item><json:item><name>Christopher Goetz MD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Dag Aarsland MD, PhD</name><affiliations><json:string>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</json:string><json:string>School of Medicine, University of Bergen, Norway</json:string></affiliations></json:item><json:item><name>Richard G. Brown PhD</name><affiliations><json:string>Department of Psychology, King's College, London, United Kingdom</json:string><json:string>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Gerald A. Broe HB, BS</name><affiliations><json:string>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</json:string><json:string>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</json:string></affiliations></json:item><json:item><name>Dennis Dickson MD</name><affiliations><json:string>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</json:string></affiliations></json:item><json:item><name>Charles Duyckaerts MD, PhD</name><affiliations><json:string>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</json:string></affiliations></json:item><json:item><name>Jefferey Cummings MD</name><affiliations><json:string>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>Serge Gauthier MD</name><affiliations><json:string>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</json:string></affiliations></json:item><json:item><name>Amos Korczyn MD, MSc</name><affiliations><json:string>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>Andrew Lees FRCP</name><affiliations><json:string>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Richard Levy MD, PhD</name><affiliations><json:string>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</json:string></affiliations></json:item><json:item><name>Irene Litvan MD</name><affiliations><json:string>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</json:string></affiliations></json:item><json:item><name>Yoshikuni Mizuno MD</name><affiliations><json:string>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>Ian G. McKeith MD</name><affiliations><json:string>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</json:string></affiliations></json:item><json:item><name>C. Warren Olanow MD</name><affiliations><json:string>Department of Neurology, Mount Sinai School of Medicine, New York, USA</json:string><json:string>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD, PhD</name><affiliations><json:string>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</json:string></affiliations></json:item><json:item><name>Eduardo Tolosa MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</json:string></affiliations></json:item><json:item><name>Murat Emre MD</name><affiliations><json:string>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PD dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>diagnostic criteria</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>executive functions</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>task force</value></json:item></subject><articleId><json:string>MDS21844</json:string></articleId><arkIstex>ark:/67375/WNG-M93B52PL-J</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>9.64</score><pdfWordCount>7054</pdfWordCount><pdfCharCount>45141</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>11</pdfPageCount><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>220</abstractWordCount><abstractCharCount>1399</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><pmid><json:string>18098298</json:string></pmid><genre><json:string>review-article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>22</volume><issue>16</issue><pages><first>2314</first><last>2324</last><total>11</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Viewpoint</value></json:item></subject></host><namedEntities><unitex><date><json:string>2007</json:string><json:string>2319</json:string><json:string>1-2-3</json:string></date><geogName></geogName><orgName><json:string>Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</json:string><json:string>McGill Center</json:string><json:string>Neuropathology Laboratory, Salpetriere Hospital, Paris</json:string><json:string>Stavanger University Hospital, Stavanger, Norway</json:string><json:string>Newcastle University, United Kingdom</json:string><json:string>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</json:string><json:string>Neurodegeneration Research, Institute of Psychiatry, King</json:string><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string><json:string>Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</json:string><json:string>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo</json:string><json:string>University of Bergen, Norway</json:string><json:string>Newcastle University</json:string><json:string>Marie Curie University</json:string><json:string>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</json:string><json:string>Hospital Clinic</json:string><json:string>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</json:string><json:string>Department of Neurology, Mount Sinai School of Medicine, New York, USA</json:string><json:string>Neurology Department and Inserm U</json:string><json:string>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</json:string><json:string>Department of Neurology, The National Hospital for Neurology and Neurosurgery</json:string><json:string>Department of Neurology, David Geffen School of Medicine</json:string><json:string>Department of Neurology, Behavioral Neurology and Movement</json:string><json:string>American Psychiatric Association</json:string><json:string>Institute for Ageing and Health</json:string><json:string>Department of Psychology, King</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Brain Bank</json:string><json:string>Ian G. McKeith</json:string><json:string>Charles Duyckaerts</json:string><json:string>Test</json:string><json:string>Murat Emre</json:string><json:string>Irene Litvan</json:string><json:string>Andrew Lees</json:string><json:string>Dennis Dickson</json:string><json:string>Celine Goetz</json:string><json:string>Yoshikuni Mizuno</json:string><json:string>Jefferey Cummings</json:string><json:string>In</json:string><json:string>The</json:string><json:string>Amos Korczyn</json:string><json:string>Tests</json:string><json:string>Warren Olanow</json:string><json:string>David Burn</json:string><json:string>A. Broe</json:string><json:string>Eduardo Tolosa</json:string><json:string>Cutoff</json:string><json:string>Werner Poewe</json:string><json:string>Force</json:string><json:string>Bruno Dubois</json:string><json:string>Cristina Sampaio</json:string><json:string>Serge Gauthier</json:string><json:string>Richard G. Brown</json:string><json:string>Richard Levy</json:string><json:string>Prince</json:string><json:string>Christopher Goetz</json:string></persName><placeName><json:string>Paris</json:string><json:string>Newcastle upon Tyne</json:string><json:string>Montreal</json:string><json:string>Turkey</json:string><json:string>Canada</json:string><json:string>London</json:string><json:string>Los Angeles</json:string><json:string>Japan</json:string><json:string>Barcelona</json:string><json:string>Tokyo</json:string><json:string>United Kingdom</json:string><json:string>Portugal</json:string><json:string>Israel</json:string><json:string>Saint Antoine</json:string><json:string>France</json:string><json:string>Quebec</json:string><json:string>Istanbul</json:string><json:string>Spain</json:string></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-M93B52PL-J</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - clinical neurology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - neurology & neurosurgery</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Clinical Neurology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Neuroscience</json:string><json:string>3 - Neurology</json:string></scopus><inist><json:string>1 - sciences humaines et sociales</json:string></inist></categories><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21844</json:string></doi><id>6E57B2447643E9AF227ECAC3B1DF8B327F449F2D</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Copyright © 2007 Movement Disorder Society</licence></availability><date type="published" when="2007-12-15"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main" xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><title level="a" type="short" xml:lang="en">Diagnostic Procedures for PD Dementia</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Bruno</forename><surname>Dubois</surname><roleName type="degree">MD</roleName></persName><email>bruno.dubois@psl.aphp.fr</email><affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France<address><country key="FR"></country></address></affiliation><affiliation>Neurology Department and Inserm U610, Salpêtrière Hospital, 47 Bd de l'Hôpital, Paris 75013, France</affiliation></author><author xml:id="author-0001"><persName><forename type="first">David</forename><surname>Burn</surname><roleName type="degree">MD</roleName></persName><affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom<address><country key="GB"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Christopher</forename><surname>Goetz</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA<address><country key="US"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Dag</forename><surname>Aarsland</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway<address><country key="NO"></country></address></affiliation><affiliation>School of Medicine, University of Bergen, Norway<address><country key="NO"></country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Richard G.</forename><surname>Brown</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Psychology, King's College, London, United Kingdom<address><country key="GB"></country></address></affiliation><affiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom<address><country key="GB"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Gerald A.</forename><surname>Broe</surname><roleName type="degree">HB, BS</roleName></persName><affiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia<address><country key="AU"></country></address></affiliation><affiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia<address><country key="AU"></country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Dennis</forename><surname>Dickson</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA<address><country key="US"></country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">Charles</forename><surname>Duyckaerts</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">Jefferey</forename><surname>Cummings</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA<address><country key="US"></country></address></affiliation></author><author xml:id="author-0009"><persName><forename type="first">Serge</forename><surname>Gauthier</surname><roleName type="degree">MD</roleName></persName><affiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada<address><country key="CA"></country></address></affiliation></author><author xml:id="author-0010"><persName><forename type="first">Amos</forename><surname>Korczyn</surname><roleName type="degree">MD, MSc</roleName></persName><affiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel<address><country key="IL"></country></address></affiliation></author><author xml:id="author-0011"><persName><forename type="first">Andrew</forename><surname>Lees</surname><roleName type="degree">FRCP</roleName></persName><affiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom<address><country key="GB"></country></address></affiliation></author><author xml:id="author-0012"><persName><forename type="first">Richard</forename><surname>Levy</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0013"><persName><forename type="first">Irene</forename><surname>Litvan</surname><roleName type="degree">MD</roleName></persName><affiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA<address><country key="US"></country></address></affiliation></author><author xml:id="author-0014"><persName><forename type="first">Yoshikuni</forename><surname>Mizuno</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan<address><country key="JP"></country></address></affiliation></author><author xml:id="author-0015"><persName><forename type="first">Ian G.</forename><surname>McKeith</surname><roleName type="degree">MD</roleName></persName><affiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom<address><country key="GB"></country></address></affiliation></author><author xml:id="author-0016"><persName><forename type="first">C. Warren</forename><surname>Olanow</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA<address><country key="US"></country></address></affiliation><affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA<address><country key="US"></country></address></affiliation></author><author xml:id="author-0017"><persName><forename type="first">Werner</forename><surname>Poewe</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria<address><country key="AT"></country></address></affiliation></author><author xml:id="author-0018"><persName><forename type="first">Cristina</forename><surname>Sampaio</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal<address><country key="PL"></country></address></affiliation></author><author xml:id="author-0019"><persName><forename type="first">Eduardo</forename><surname>Tolosa</surname><roleName type="degree">MD</roleName></persName><affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain<address><country key="ES"></country></address></affiliation></author><author xml:id="author-0020"><persName><forename type="first">Murat</forename><surname>Emre</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey<address><country key="TR"></country></address></affiliation></author><idno type="istex">6E57B2447643E9AF227ECAC3B1DF8B327F449F2D</idno><idno type="ark">ark:/67375/WNG-M93B52PL-J</idno><idno type="DOI">10.1002/mds.21844</idno><idno type="unit">MDS21844</idno><idno type="toTypesetVersion">file:MDS.MDS21844.pdf</idno></analytic><monogr><title level="j" type="main">Movement Disorders</title><title level="j" type="alt">MOVEMENT DISORDERS</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="book-DOI">10.1002/(ISSN)1531-8257</idno><idno type="book-part-DOI">10.1002/mds.v22:16</idno><idno type="product">MDS</idno><imprint><biblScope unit="vol">22</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2314">2314</biblScope><biblScope unit="page" to="2324">2324</biblScope><biblScope unit="page-count">11</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-12-15"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">Parkinson's disease</term><term xml:id="kwd2">PD dementia</term><term xml:id="kwd3">diagnostic criteria</term><term xml:id="kwd4">executive functions</term><term xml:id="kwd5">task force</term></keywords><keywords rend="articleCategory"><term>Viewpoint</term></keywords><keywords rend="tocHeading1"><term>Viewpoint</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="160"><doi origin="wiley" registered="yes">10.1002/mds.v22:16</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">16</numbering></numberingGroup><coverDate startDate="2007-12-15">15 December 2007</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="30" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21844</doi><idGroup><id type="unit" value="MDS21844"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Viewpoint</title><title type="tocHeading1">Viewpoint</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-02-12"></event><event type="manuscriptRevised" date="2007-08-03"></event><event type="manuscriptAccepted" date="2007-10-16"></event><event type="firstOnline" date="2007-12-20"></event><event type="publishedOnlineFinalForm" date="2007-12-20"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2314</numbering><numbering type="pageLast">2324</numbering></numberingGroup><correspondenceTo>Neurology Department and Inserm U610, Salpêtrière Hospital, 47 Bd de l'Hôpital, Paris 75013, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21844.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="70"></count><count type="wordTotal" number="7944"></count></countGroup><titleGroup><title type="main" xml:lang="en">Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title><title type="short" xml:lang="en">Diagnostic Procedures for PD Dementia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Bruno</givenNames><familyName>Dubois</familyName><degrees>MD</degrees></personName><contactDetails><email>bruno.dubois@psl.aphp.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>David</givenNames><familyName>Burn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Christopher</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4 #af5"><personName><givenNames>Dag</givenNames><familyName>Aarsland</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af6 #af7"><personName><givenNames>Richard G.</givenNames><familyName>Brown</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af8 #af9"><personName><givenNames>Gerald A.</givenNames><familyName>Broe</familyName><degrees>HB, BS</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Dennis</givenNames><familyName>Dickson</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Charles</givenNames><familyName>Duyckaerts</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Jefferey</givenNames><familyName>Cummings</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af13"><personName><givenNames>Serge</givenNames><familyName>Gauthier</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af14"><personName><givenNames>Amos</givenNames><familyName>Korczyn</familyName><degrees>MD, MSc</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af15"><personName><givenNames>Andrew</givenNames><familyName>Lees</familyName><degrees>FRCP</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af16"><personName><givenNames>Richard</givenNames><familyName>Levy</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af17"><personName><givenNames>Irene</givenNames><familyName>Litvan</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af18"><personName><givenNames>Yoshikuni</givenNames><familyName>Mizuno</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au16" creatorRole="author" affiliationRef="#af19"><personName><givenNames>Ian G.</givenNames><familyName>McKeith</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au17" creatorRole="author" affiliationRef="#af20 #af21"><personName><givenNames>C. Warren</givenNames><familyName>Olanow</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au18" creatorRole="author" affiliationRef="#af22"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au19" creatorRole="author" affiliationRef="#af23"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au20" creatorRole="author" affiliationRef="#af24"><personName><givenNames>Eduardo</givenNames><familyName>Tolosa</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au21" creatorRole="author" affiliationRef="#af25"><personName><givenNames>Murat</givenNames><familyName>Emre</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="NO" type="organization"><unparsedAffiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="NO" type="organization"><unparsedAffiliation>School of Medicine, University of Bergen, Norway</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="GB" type="organization"><unparsedAffiliation>Department of Psychology, King's College, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="GB" type="organization"><unparsedAffiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="AU" type="organization"><unparsedAffiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="AU" type="organization"><unparsedAffiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="US" type="organization"><unparsedAffiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="FR" type="organization"><unparsedAffiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af13" countryCode="CA" type="organization"><unparsedAffiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af14" countryCode="IL" type="organization"><unparsedAffiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af15" countryCode="GB" type="organization"><unparsedAffiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af16" countryCode="FR" type="organization"><unparsedAffiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af17" countryCode="US" type="organization"><unparsedAffiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</unparsedAffiliation></affiliation><affiliation xml:id="af18" countryCode="JP" type="organization"><unparsedAffiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</unparsedAffiliation></affiliation><affiliation xml:id="af19" countryCode="GB" type="organization"><unparsedAffiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af20" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af21" countryCode="US" type="organization"><unparsedAffiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af22" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af23" countryCode="PL" type="organization"><unparsedAffiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af24" countryCode="ES" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af25" countryCode="TR" type="organization"><unparsedAffiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">PD dementia</keyword><keyword xml:id="kwd3">diagnostic criteria</keyword><keyword xml:id="kwd4">executive functions</keyword><keyword xml:id="kwd5">task force</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Diagnostic Procedures for PD Dementia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force</title></titleInfo><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Dubois</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM‐UPMC UMRS 610, Federation of Neurology, AP‐HP, Salpêtrière Hospital; Université Paris6, Paris, France</affiliation><affiliation>E-mail: bruno.dubois@psl.aphp.fr</affiliation><affiliation>Correspondence address: Neurology Department and Inserm U610, Salpêtrière Hospital, 47 Bd de l'Hôpital, Paris 75013, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Burn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute for Ageing and Health, Newcastle University, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dag</namePart><namePart type="family">Aarsland</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway</affiliation><affiliation>School of Medicine, University of Bergen, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard G.</namePart><namePart type="family">Brown</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychology, King's College, London, United Kingdom</affiliation><affiliation>MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gerald A.</namePart><namePart type="family">Broe</namePart><namePart type="termsOfAddress">HB, BS</namePart><affiliation>Ageing Research Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia</affiliation><affiliation>Faculty of Medicine, Prince of Wales Medical Research Institute, University of New South Wales, Randwick, New South Wales, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dennis</namePart><namePart type="family">Dickson</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Charles</namePart><namePart type="family">Duyckaerts</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neuropathology Laboratory, Salpetriere Hospital, Paris VI Pierre et Marie Curie University, Inserm U679, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jefferey</namePart><namePart type="family">Cummings</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Serge</namePart><namePart type="family">Gauthier</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Alzheimer Disease and Related Disorders Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Amos</namePart><namePart type="family">Korczyn</namePart><namePart type="termsOfAddress">MD, MSc</namePart><affiliation>Department of Neurology, Tel‐Aviv University, Ramat ‐Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">FRCP</namePart><affiliation>Department of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Levy</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>INSERM U610, Hôpital de la Salpêtrière & AP‐HP, Hôpital Saint Antoine, Service de Neurologie, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Irene</namePart><namePart type="family">Litvan</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yoshikuni</namePart><namePart type="family">Mizuno</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Research Institute for Diseases of Old Ages, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ian G.</namePart><namePart type="family">McKeith</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. Warren</namePart><namePart type="family">Olanow</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, USA</affiliation><affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratorio de Farmacologia Clinica e Terapeutica, Faculdade de Medicina de Lisboa e Instituto de Medicina Molecular, Lisboa, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eduardo</namePart><namePart type="family">Tolosa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clinic de Neurociences, Hospital Clinic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERNED, Barcelona, Catalonia, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Murat</namePart><namePart type="family">Emre</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Ístanbul Faculty of Medicine, Ístanbul University, Ístanbul, Turkey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-12-15</dateIssued><dateCaptured encoding="w3cdtf">2007-02-12</dateCaptured><dateValid encoding="w3cdtf">2007-10-16</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">3</extent><extent unit="references">70</extent><extent unit="words">7944</extent></physicalDescription><abstract lang="en">A preceding article described the clinical features of Parkinson's disease dementia (PD‐D) and proposed clinical diagnostic criteria for “probable” and “possible” PD‐D. The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time‐consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD‐D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD‐D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence‐based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>keywords</genre><topic>Parkinson's disease</topic><topic>PD dementia</topic><topic>diagnostic criteria</topic><topic>executive functions</topic><topic>task force</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Viewpoint</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>16</number></detail><extent unit="pages"><start>2314</start><end>2324</end><total>11</total></extent></part></relatedItem><identifier type="istex">6E57B2447643E9AF227ECAC3B1DF8B327F449F2D</identifier><identifier type="ark">ark:/67375/WNG-M93B52PL-J</identifier><identifier type="DOI">10.1002/mds.21844</identifier><identifier type="ArticleID">MDS21844</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/6E57B2447643E9AF227ECAC3B1DF8B327F449F2D/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001468 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001468 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6E57B2447643E9AF227ECAC3B1DF8B327F449F2D
|texte= Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
}}
| This area was generated with Dilib version V0.6.33. |  |